Wockhardt Intrinsic Value
Wockhardt intrinsic value. Wockhardt (WOCKPHARMA) median intrinsic value is ₹874.80 from 9 valuation models (range ₹656–₹1304), vs current price ₹2187.00 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse WOCKPHARMA shareholding pattern to track promoter, FII and institutional holdings.
WOCKPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Wockhardt intrinsic value across 9 models vs current price ₹2187.00 — upside/downside and value range per method. For current market price and key ratios, visit Wockhardt screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹656.10 | ₹524.88 - ₹787.32 | -70.0% | EPS: ₹19.40, Sector P/E: 22x |
| Book Value Method | asset | ₹1303.95 | ₹1173.56 - ₹1434.35 | -40.4% | Book Value/Share: ₹651.98, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹967.90 | ₹871.11 - ₹1064.69 | -55.7% | Revenue/Share: ₹483.95, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹908.64 | ₹817.78 - ₹999.50 | -58.5% | EBITDA: ₹736.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹874.80 | ₹699.84 - ₹1049.76 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹656.10 | ₹590.49 - ₹721.71 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹656.10 | ₹590.49 - ₹721.71 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1093.50 | ₹984.15 - ₹1202.85 | -50.0% | ROE: 5.5%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹656.10 | ₹590.49 - ₹721.71 | -70.0% | EPS: ₹19.40, BVPS: ₹651.98 |
WOCKPHARMA Intrinsic Value vs Market Price — All Valuation Models
Wockhardt fair value range ₹656–₹1304 vs current market price ₹2187.00 across 9 valuation models. Browse WOCKPHARMA financial statements for revenue, profit, balance sheet and cash flow data.
WOCKPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Wockhardt median intrinsic value ₹874.80, current price ₹2187.00 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of WOCKPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Wockhardt (WOCKPHARMA) is ₹874.80 (median value). With the current market price of ₹2187.00, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹656.10 to ₹1303.95, indicating ₹656.10 - ₹1303.95.
Is WOCKPHARMA undervalued or overvalued?
Based on our multi-method analysis, Wockhardt (WOCKPHARMA) appears to be trading above calculated value by approximately 60.0%.
WOCKPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Wockhardt financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 5.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.46x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
WOCKPHARMA Cash Flow Quality — Operating & Free Cash Flow
Wockhardt operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹390 Cr | ₹275 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹-22 Cr | ₹-412 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹219 Cr | ₹150 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹153 Cr | ₹94 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹413 Cr | ₹311 Cr | Positive Free Cash Flow | 8/10 |